ALLMedicine™ Langerhans Cell Sarcoma Center
Research & Reviews 57 results
https://doi.org/10.1186/s13256-020-02460-3
Journal of Medical Case Reports; Aguirre LE, Schwartz I et. al.
Sep 27th, 2020 - Langerhans cell tumors are rare clonal disorders characterized by neoplastic proliferation of dendritic cells that can be further classified into the subtypes Langerhans cell histiocytosis and Langerhans cell sarcoma, which are rare neoplasms exhi...
https://doi.org/10.1111/cup.13803
Journal of Cutaneous Pathology; Ronen S, Keiser E et. al.
Jul 9th, 2020 - Langerhans cell sarcoma (LCS) is rare and aggressive; patients have an overall survival rate of less than 50%. We present a 62-year-old man with a history of superficial spreading melanoma of the upper back with sentinel lymph node metastasis, Lan...
https://doi.org/10.1111/cup.13571
Journal of Cutaneous Pathology REFERENCES; Papoudou-Bai A, Vassou A et. al.
Aug 23rd, 2019 - The phenomenon of histiocytic/dendritic cell sarcomas arising through transformation of a pre-existed lymphoproliferative disease is called transdifferentiation. Langerhans cell sarcoma transdifferentiating from chronic lymphocytic leukemia/small ...
https://doi.org/10.1016/j.clml.2019.03.026
Clinical Lymphoma, Myeloma & Leukemia; Tella SH, Kommalapati A et. al.
Apr 21st, 2019 - Limited knowledge exists on the incidence, treatment patterns, and long-term outcomes of Langerhans cell sarcoma (LCS) in the United States. We performed a retrospective study of LCS patients diagnosed between 2001 and 2014 using the Surveillance,...
https://doi.org/10.1093/annonc/mdz125
Annals of Oncology : Official Journal of the European Soc... Jouenne F, De Moura CR et. al.
Apr 11th, 2019 - RASA1 loss in a BRAF-mutated Langerhans cell sarcoma: a mechanism of resistance to BRAF inhibitor.|2019|Jouenne F,De Moura CR,Lorillon G,Meignin V,Dumaz N,|
Clinicaltrials.gov 57 results
https://doi.org/10.1186/s13256-020-02460-3
Journal of Medical Case Reports; Aguirre LE, Schwartz I et. al.
Sep 27th, 2020 - Langerhans cell tumors are rare clonal disorders characterized by neoplastic proliferation of dendritic cells that can be further classified into the subtypes Langerhans cell histiocytosis and Langerhans cell sarcoma, which are rare neoplasms exhi...
https://doi.org/10.1111/cup.13803
Journal of Cutaneous Pathology; Ronen S, Keiser E et. al.
Jul 9th, 2020 - Langerhans cell sarcoma (LCS) is rare and aggressive; patients have an overall survival rate of less than 50%. We present a 62-year-old man with a history of superficial spreading melanoma of the upper back with sentinel lymph node metastasis, Lan...
https://doi.org/10.1111/cup.13571
Journal of Cutaneous Pathology REFERENCES; Papoudou-Bai A, Vassou A et. al.
Aug 23rd, 2019 - The phenomenon of histiocytic/dendritic cell sarcomas arising through transformation of a pre-existed lymphoproliferative disease is called transdifferentiation. Langerhans cell sarcoma transdifferentiating from chronic lymphocytic leukemia/small ...
https://doi.org/10.1016/j.clml.2019.03.026
Clinical Lymphoma, Myeloma & Leukemia; Tella SH, Kommalapati A et. al.
Apr 21st, 2019 - Limited knowledge exists on the incidence, treatment patterns, and long-term outcomes of Langerhans cell sarcoma (LCS) in the United States. We performed a retrospective study of LCS patients diagnosed between 2001 and 2014 using the Surveillance,...
https://doi.org/10.1093/annonc/mdz125
Annals of Oncology : Official Journal of the European Soc... Jouenne F, De Moura CR et. al.
Apr 11th, 2019 - RASA1 loss in a BRAF-mutated Langerhans cell sarcoma: a mechanism of resistance to BRAF inhibitor.|2019|Jouenne F,De Moura CR,Lorillon G,Meignin V,Dumaz N,|
